For example, therapeutic monoclonal antibodies against EGFR, such as Cetuximab and Panitumumab, are poorly effective in KRAS/NRAS-mutated colorectal cancers, that is, for ~40% of the patients [24]. The gene discussed is EGFR; the disease is colorectal cancer.